IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats
Article first published online: 6 MAR 2007
Copyright © 2007 Wiley-Liss, Inc.
Volume 67, Issue 7, pages 701–713, 15 May 2007
How to Cite
Rajeshkumar, N.V., Matwyshyn, G. and Gulati, A. (2007), IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate, 67: 701–713. doi: 10.1002/pros.20556
- Issue published online: 28 MAR 2007
- Article first published online: 6 MAR 2007
- Manuscript Accepted: 6 DEC 2006
- Manuscript Received: 22 JUN 2006
- NCRR NIH. Grant Number: C06RR15482
- tumor blood flow;
IRL-1620, a potent endothelin B receptor agonist, enhanced the efficacy of paclitaxel in a breast tumor model, but its effect in prostate cancer is not known. The present study was conducted to evaluate the effect of IRL-1620 on tumor perfusion, uptake of [14C]-doxorubicin in the tumor and efficacy of doxorubicin (DOX), and 5-flurouracil (5-FU) in a rat prostate tumor model.
JHU-4 (Mat-Lu) cells inoculated prostate tumor model in Copenhagen rats was used for the study.
Administration of IRL-1620 (3 nmol/kg, i.v) significantly increased (102.8%) prostate tumor perfusion and tumor uptake of [14C]-doxorubicin (115%) compared to vehicle treated rats. Results of the efficacy study demonstrate that IRL-1620 administration 15 min prior to DOX (5 mg/kg) or 5-FU (50 mg/kg) on every third day for a total of four doses significantly reduced tumor volume compared to vehicle treated rats.
IRL-1620 significantly enhanced the uptake and efficacy of anticancer agents in prostate cancer. Prostate 67: 701–713, 2007. © 2007 Wiley-Liss, Inc.